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 4 
Comparison against external datasets 5 
We compared our findings against three publicly available RNA-seq datasets from 6 
studies of SARS-CoV-2 infection1–3. Given that no prior lower respiratory fluid transcriptomic 7 
studies have focused specifically on patients with ARDS, the most relevant comparison was with 8 
respect to our COVID-ARDS versus No-ARDS analysis, although we also compared against our 9 
COVID-ARDS versus Bacterial LRTI-ARDS analysis, which had a larger sample size.   10 
We first assessed our findings against a study of post-mortem lung tissue from COVID-19 11 
or control patients1 and identified overlapping differentially expressed genes (Supplementary 12 
Data 12a) related to chemokine signaling, type 1 interferon signaling and toll like receptor 13 
signaling pathways, which were upregulated in the COVID-19 groups (Supplementary Data 12b). 14 
We subsequently compared our results to a study evaluating BAL gene expression in a rhesus 15 
macaque model of SARS-CoV-2 infection2 and also identified overlapping differentially 16 
expressed genes with respect to our COVID-ARDS versus No-ARDS analysis (Supplementary 17 
Data 12c). Functional enrichment of the genes upregulated SARS-CoV-2 infection identified 18 
pathways related to interferon signaling, coronavirus pathogenesis and cytokine signaling 19 
(Supplementary Data 12d).  20 
In addition, we evaluated our data against a recently published BAL transcriptional 21 
profiling dataset of COVID-19 patients and controls with or without pneumonia3 and identified 22 
overlapping differentially expressed genes (Supplementary Data 12e) representing pathways 23 
including interferon-gamma signaling and SARS-CoV-2 innate immunity evasion in the patients 24 
with COVID-19 (Supplemental Data 12f).  We also found significant overlap of differentially 25 
expressed genes with respect to the COVID-19 vs bacterial pneumonia comparison in this study 26 
and our COVID-ARDS versus Bacterial-LRTI ARDS analysis (Supplementary Data 12g). 27 
Functional enrichment analysis demonstrated that shared differentially expressed genes 28 
upregulated in COVID-19 patients across both studies represented pathways including the host 29 
anti-viral response (Supplementary Data 12h) and those upregulated in patients with bacterial 30 
pneumonia in both studies represented IL-1, TLR and myeloid cell activation pathways 31 
(Supplementary Data 12i). We note that these external studies did not exclude COVID-19 32 
patients receiving immunosuppressants, a criterion that we imposed to ensure transcriptional 33 
profiling results (in particular those related to immune signaling) most accurately reflected the 34 
underlying biology of disease. 35 
 36 
Comparison against matched TA and mini-BAL samples 37 
Because bronchial alveolar lavage (BAL) fluid has been used more frequently than TA to 38 
study the lower respiratory tract of COVID-19 patients2–5, we compared in silico cell type 39 
deconvolution of RNA-seq data from eight subjects with matched TA and mini-BAL specimens 40 
from a previously published study in the control cohort6. No significant differences in cell type 41 
proportions were observed, suggesting that TA had the potential to comparably assesses the 42 
lower respiratory tract transcriptional environment of patients with pneumonia (Supplementary 43 
Data 13, Supplementary Figure 7).  44 
45 
Supplementary Figures 46 
 47 
 48 
Supplementary Figure 1. CONSORT diagram depicting patient enrollment. We analyzed all 49 
subjects with TA specimens available for RNA-seq who either: 1) had clinically adjudicated 50 
acute respiratory distress syndrome (ARDS) due to other viral, bacterial, or non-infectious 51 
etiologies (COVID-ARDS, Other-ARDS groups), or who were intubated for airway protection 52 
without radiographic evidence of pulmonary pathology (No-ARDS group).  Of the 360 enrolled 53 
subjects, 86 had TA samples available for RNA-seq. Subjects who withdrew consent (n=1), who 54 
had LRTI but no ARDS (n=2), who did not have a TA sample collected within five days of 55 
intubation (n=7), or who had TA samples yielding < 1x106 protein-coding transcripts on RNA-56 
seq (n=1), were excluded. Of the remaining 75 eligible subjects, those treated with 57 
immunosuppression or with underlying immunocompromising conditions were excluded, leaving 58 
15 COVID-ARDS, 32 Other-ARDS and five No-ARDS subjects for final analysis.  59 
24 subjects with 
COVID ARDS
15 COVID ARDS subjects 
included in final analysis
43 subjects with
Other ARDS




5 No ARDS subjects 
included in final analysis
86 subjects with ARDS, LRTI, or without 
radiographic evidence of pulmonary disease, 
and TA samples available for RNA-seq
75 eligible subjects
• 1 subject withdrew consent 
• 2 subjects with evidence of 
LRTI but no ARDS
• 7 subjects without sample 
within 5 days of intubation
• 1 subject with < 1 million 
transcripts on TA RNA-seq
Exclusion of patients treated with immunosuppressants or with underlying immunocompromising conditions




Supplementary Figure 2. Principal component analysis of gene expression in TA samples. 62 
The plotPCA function in DESeq2 was used to analyze the 500 genes with the highest variance 63 
in TA samples from in TA samples from the COVID-ARDS, Other-ARDS and No-ARDS 64 
groups.  65 
  66 
Supplementary Figure 3. Normalized expression of genes differentially expressed between 67 
COVID-ARDS and Other-ARDS groups also predicted to be most inhibited by both 68 
dexamethasone and G-CSF. Normalized expression for COVID-ARDS (red, n=15), Other-69 
ARDS (violet, n=32), and No-ARDS controls (grey, n=5) were compared using a two-sided Wald 70 
test in DESeq 2. Adjustments for multiple comparisons were made using the independent 71 
hypothesis weighted Benjamini-Hochberg adjusted P-value, which is indicated above the bar 72 
spanning each comparator group. Complete list of genes inhibited or activated by 73 
dexamethasone, G-CSF and other drugs computationally predicted by IPA to modulate the 74 
transcriptional response of COVID-ARDS against a comparator groups is found in 75 
Supplementary Data 6. Source data can be found in the Source Data file.  Lines depict median 76 
























Supplementary Figure 4. In silico deconvolution of cell types from tracheal aspirate bulk 79 
RNA-sequencing data using lung single cell signatures. The horizontal line inside the box 80 
denotes the median and the lower and upper hinges correspond to the first and third quartiles, 81 
respectively. Whiskers extend from the hinge to the largest (smallest, respectively) value no 82 
more than 1.5*IQR away from the hinge, where IQR is the interquartile range. The y-axis in 83 
each panel was trimmed at the maximum value among the three patient groups of 1.5*IQR 84 
above the third quartile. Pairwise comparisons between patient groups were performed with a 85 
two-sided Mann-Whitney-Wilcoxon test followed by Bonferroni’s correction (n=15 COVID-ARDS, 86 
n=32 Other ARDS, n=5 No-ARDS). Data are tabulated in (Supplementary Data 7) and can be 87 
found in the Source Data file.   88 
89 
Supplementary Figure 5. Principal component analysis of gene expression in samples 90 
used for subgroup analysis. The plotPCA function in DESeq2 was used to analyze the 500 91 
genes with the highest variance in TA samples from COVID-ARDS, Viral LRTI-ARDS, Bacterial 92 
LRTI-ARDS, and No-ARDS groups.  93 
 94 
 95 
Supplementary Figure 6. Relationship between SARS-CoV-2 viral load and interferon-96 
stimulated gene (ISG) expression. a) Scatterplot of the relationship between ISG counts and 97 
SARS-CoV-2 viral load (reads per million, rpM), quantified by the regression slope, in 98 
nasopharyngeal (NP) samples from patients with mostly mild/early COVID-19 (x-axis) and in 99 
tracheal aspirate (TA) samples from patients with severe COVID-19 and ARDS (y-axis). b) 100 
Scatter plots of normalized gene counts (log2 scale, y-axis) as a function of SARS-CoV-2 viral 101 
load (log10(rpM), x-axis). Robust regression was performed on SARS-CoV-2 positive patients. 102 
Lines represent the regression estimates and shaded bands represent 95% confidence 103 




(x-axis) in both early/mild (NP) and severe (TA) disease, while OASL is an ISG for which the 105 
correlation observed in early/mild COVID-19 is absent in severe COVID-19 patients with ARDS. 106 




Supplementary Figure 7. Cell type proportions in matched TA and mini-BAL samples. In 111 
silico deconvolution of cell types using lung single cell signatures from matched TA and mini-112 
BAL samples (n=8) from patients with bacterial LRTI in the control cohort that underwent bulk 113 
RNA-sequencing. The horizontal line inside the box denotes the median and the lower and 114 
upper hinges correspond to the first and third quartiles, respectively. Whiskers extend from the 115 
hinge to the largest (smallest, respectively) value no more than 1.5*IQR away from the hinge, 116 
where IQR is the interquartile range. The y-axis in each panel was trimmed at the maximum 117 
value among the three patient groups of 1.5*IQR above the third quartile. Pairwise comparisons 118 
between patient groups were performed with a two-sided Mann-Whitney-Wilcoxon test followed 119 
by Bonferroni’s correction. Values are tabulated in (Supplementary Data 13) and can be found 120 
in the Source Data file.  121 
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